A recent retrospective study from Japan comparing non-small cell lung cancer patients who received systemic corticosteroids for anti-PD-1 related irAEs to those who did not develop irAEs or receive corticosteroids for irAEs found that progression free survival was significantly shorter in patients who received systemic corticosteroids (11.7 vs. 16.0 months; p = 0.037) (54). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.